Ann: Top 20 Shareholders Update, page-165

this is one of the first companies in the world doing this trail. they are pioneering the development and commercialisation of new classes of synthetic antibiotics to address the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens . so since the antibiotic is synthetic (man-made) the bacteria and viruses are less likely to become resistant or tolerant against it unlike normal antibiotics and vaccines. that's why sometimes vaccines and antibiotics become ineffective/less effective after sometime because it's not fully synthetic .